Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction. Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the offering. Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Imago BioSciences, Inc. in the offering. Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wachtell, Lipton, Rosen & Katz represented Ginkgo Bioworks, while White & Case LLP advised Soaring Eagle Acquisition Corp. in the transaction....
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
You must be a Standard 1 Year member to access this content.
